The trial stopping rule is based on Bayesian monitoring of safety at the lowest
dose level. The rationale is that if even the lowest dose shows excessive toxicity
with high posterior probability, all doses in the trial may be too toxic, warranting
early trial termination.
The posterior probability Pr(p > target | data) is computed using Beta-Binomial
conjugate prior with uniform prior (Beta(1,1)). The stopping rule is not evaluated
until at least 3 patients have been treated at the lowest dose.